STSophie Taieb

Sophie Taieb

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sophie Taieb has a total of 135 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • ASO Visual Abstract: Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial

    by Sylvie Bonvalot, Nathalie Cozic, Axel Le Cesne, Jean Yves Blay, Nicolas Penel, Magali Fau, Christine Chevreau, Philippe Anract, Denis Waast, Valérie Laurence, et al.


  • Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial

    by Sylvie Bonvalot, Nathalie Cozic, Axel Le Cesne, Jean Yves Blay, Nicolas Penel, Magali Fau, Christine Chevreau, Philippe Anract, Denis Waast, Valérie Laurence, et al.

    Stabilization or spontaneous regressions are demonstrated in more than half of patients affected by primary desmoid-type fibromatosis (DF) in retrospective


  • Open Access

    Diagnostic Value of the Texture Analysis Parameters of Retroperitoneal Residual Masses on Computed Tomographic Scan after Chemotherapy in Non-Seminomatous Germ Cell Tumors

    by Clémence Fournier, Clémence Leguillette, Eric Leblanc, Marie-Cécile Le Deley, Aurélien Carnot, David Pasquier, Alexandre Escande, Sophie Taieb, Luc Ceugnart, Loïc Lebellec

    After chemotherapy, patients with non-seminomatous germ cell tumors (NSGCTs) with residual masses >1 cm on computed tomography (CT) undergo surgery. However, in approximately 50% of cases, these masses only consist of necrosis/fibrosis. We aimed to develop a radiomics score to predict the malignant character of residual masses to avoid surgical overtreatment. Patients with NSGCTs who underwent surgery for residual masses between September 2007 and July 2020 were retrospectively identified from a unicenter database. Residual masses were delineated on post-chemotherapy contrast-enhanced CT scans. Tumor textures were obtained using the free software LifeX. We constructed a radiomics score using a penalized logistic regression model in a training dataset, and evaluated its performance on a test dataset. We included 76 patients, with 149 residual masses; 97 masses were malignant (65%). In the training dataset (n = 99 residual masses), the best model (ELASTIC-NET) led to a radiomics score based on eight texture features. In the test dataset, the area under the curve (AUC), sensibility, and specificity of this model were respectively estimated at 0.82 (95%CI, 0.69–0.95), 90.6% (75.0–98.0), and 61.1% (35.7–82.7). Our radiomics score may help in the prediction of the malignant nature of residual post-chemotherapy masses in NSGCTs before surgery, and thus limit overtreatment. However, these results are insufficient to simply select patients for surgery.


  • Ziv-aflibercept (A) combined to FOLFIRI as first line treatment for metastatic colorectal cancer (mCRC): Interim safety and efficacy results of the phase II PULSAR trial.

    by Antoine Adenis, Francois Ghiringhelli, Jean Luc Raoul, Emmanuelle Tresch, Anne Thirot-Bidault, Julie Vincent, Farid El Hajbi, Mohamed Hebbar, Mohamed Bouchahda, Hajer Jarraya, et al.

    737 Background: A is approved in combination with FOLFIRI (A-FOLFIRI) for the treatment of mCRC patients (pts) previously treated with oxaliplatin. PULSAR trial (NCT02173990) aims to measure the activity A-FOLFIRI as 1st-line mCRC treatment. Key secondary objectives are safety, as well as circulating biomarkers and dynamic contrast-enhanced ultrasound measurements as PFS prognosticators. We present here interim analysis of safety and activity. Methods: Pts received A (4 mg/kg I.V.) every 2 weeks in combination with FOLFIRI (Irinotecan: 180 mg/m2, leucovorin: 200 mg/m2, Bolus FU: 400 mg/m2, infusional FU: 2400 mg/m2 over 46hrs). The primary endpoint is 10-month [m] PFS (RECIST 1.1). The target sample size is 72 pts for the following assumptions: P0 = 0.40, P1 = 0.55, α = β = 0.1. Results: Among the first 30 recruited mCRC pts with unresectable metastases (mets), 29 received at least 1 cycle of A-FOLFIRI. 30, 23, and 28 pts were evaluable for survival (intent-to-treat), tumor response, and safety, respectively. Median age was 61.5 (45-82), 70% pts were men. ECOG PS was 0, 1, and 2, in 47%, 43%, and 10% of the pts. 6/30 pts received previous adjuvant chemotherapy. 22/30 pts presented with synchronous mets. 26/30 pts presented with liver mets. Median treatment duration was 6.3m (0.5-24.3) and pts (n = 29) received a median number of 10 cycles (1-37) of A and of 11 cycles (1-43) of FOLFIRI. Median follow-up was 7.2m (1.6-23.9). The 10-m PFS was 59.9% [95%-CI: 37.5-76.5]. Median PFS was 12.9m (95% CI: 6.1-…). 12-m OS rate was 73.7% (95% CI: 48.3-87.9). 5 pts died from PD, and 1 from treatment-related toxicity (colon perforation). 27/28 pts presented at least one severe Adverse Event (AE). Most frequent severe AE (related or not) were hypertension (43%), neutropenia (29%), diarrhea (18%), alkaline phosphatase increase (18%), fatigue (18%), GGT increase (14%), and weight loss (14%). Conclusions: A-FOLFIRI seems promising in 1st line setting mCRC, with respect to PFS. Due to high rates of severe AEs, dose modifications have to be proceeded in a coming protocol amendment. Funded by Sanofi. Clinical trial information: NCT02173990.

  • Is symptom worsening (SW) associated with RECIST response in patients (pts) with desmoid tumors (DT)?

    by Nuria Kotecki, Armelle Renaud, Mariem Ben Haj Amor, Anne-Sophie Thomassin Defachelles, Thomas Ryckewaert, Vincent Gamblin, Yves Marie Robin, Sophie Taieb, Nicolas Penel

    E22534 Background: DT is a rare, locally infiltrative tumor. Front-line 'watch-and-wait' policy with monitoring by MRI is recommended. Methods: We retrospectively reviewed data from 27 consecutive pts with histologically-proven DT from 01/2007 to 12/2015. The study aims to investigate if SW is correlated with disease progression according to RECIST 1.1, volumetric changes or contrast enhancement (CE) over time. Clinical and MRI characteristics were assessed at diagnosis and at last follow up. Results: The cohort consisted in 6 men (22%) and 21 women (77%) with a median age of 33 (10-77). The most common location was the abdominal wall (11, 40%). Median follow-up was 40 months (5-98). 15/27 (55%) pts received at least 1 systemic treatment including NSAID, tamoxifen, imatinib or methotrexate based chemotherapy. Increasing in pain, retraction, functional impairment were seen respectively in 11 (40%), 10 (37%) and 10 (37%) patients. Objective response, stable disease and disease progression according to RECIST 1.1 was found in 7 (26%), 13 (48%) and 7 (26%) pts, respectively. Objective response, stable disease and progressive disease according to volumetric changes was found in 8 (30%), 10 (37%), 9 (33%) pts, respectively. Size and volume changes were highly correlated (p < .00001.). We have described 2 “false” progressions characterized by increased of only 1 axis and decrease of other axis; this could be related to tumor retraction along the muscle fibers. We found that response assessment according RECIST was not associated with SW (Table). CE was assessable in 26 pts, with decrease CE in 10 pts (38%) and stable CE in 16 pts (62%). CE change and RECIST response were not correlated (p = 0.697). CE changes were not associated with worsening of pain (p = 0.676), retraction (p = 0.126) and functional impairment (p = 0.126) Conclusions: SW was not associated with the response according to RECIST, volumetric or CE changes. Innovative methods for monitoring pts are needed.

  • Open Access

    Lobulated Enhancement Evaluation in the Follow-Up of Liver Metastases Treated by Stereotactic Body Radiation Therapy

    by Hajer Jarraya, Paul Borde, Xavier Mirabel, Olivier Ernst, Thomas Boulanger, Eric Lartigau, Luc Ceugnart, Andrew Kramar, Sophie Taieb


  • Open Access

    Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial

    by Thomas Brodowicz, Bernadette Liegl-Atzwager, Emmanuelle Tresch, Sophie Taieb, Andrew Kramar, Viktor Gruenwald, Marie Vanseymortier, Stéphanie Clisant, Jean-Yves Blay, Axel Le Cesne, et al.

    Angiogenesis, among other signaling pathways, plays a key-role in sarcoma biology. Regorafenib (RE) has recently been shown to be effective in imatinib and sunitinib-refractory GIST in a phase III trial. We are conducting an international trial (France, Austria and Germany) consisting in 4 parallel double-blind placebo-controlled randomized (1/1) phase II trials to assess the activity and safety of RE in doxorubicin-refractory STS (ClinicalTrials.gov: NCT01900743). Each phase II trial is dedicated to one of the 4 following histological subgroups: liposarcoma, leiomyosarcoma, synovial sarcoma and other sarcoma. Within each randomized trial the following stratification factors will be applied: countries and prior exposure to pazopanib. Key-eligibility criteria are: measurable disease, age ≥18, not > 3 previous systemic treatment lines for metastatic disease, metastatic disease not amenable to surgical resection. The primary endpoint is progression-free survival (PFS) according to central radiological review. Secondary endpoints are: Toxicity (NCI-CTC AE V4.0); time to progression; Growth modulation index in pts receiving RE after randomization; 3 and 6 months PFS-Rates, best response rate and overall survival. Each phase II trial will be separately analyzed. In 3 trials, statistical assumptions are: PFS0 = 1.6 & PFS1 = 4.6 months; 1-sided α = 0.1; β = 0.05 with a total sample size of 192 pts. To take into account the rarity of synovial sarcoma, the statistical assumptions are: PFS0 = 1.6 & PFS1 = 4.6 months; 1-sided α = 0.1; β = 0.2 Tumor assessment is done monthly during the 4 first months, and every 3 months thereafter. After central radiological confirmation of tumor progression, an optional open-label option is offered to eligible patients. The design of this trial allows an assessment of regorafenib activity over placebo in four sarcoma strata and might provide evidence for launching a phase III trial. This study includes both integrative and exploratory translational research program. The study is enrolling since June 2013 (Trial Registration Number: EudraCT N°: 2012-005743-24, on the 15th February 2012).


  • Comparison of Response Evaluation Criteria in Solid Tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: A retrospective analysis

    by Sophie Taieb, Esma Saada-Bouzid, Emmanuelle Tresch, Thomas Ryckewaert, Emmanuelle Bompas, Antoine Italiano, Cécile Guillemet, Charlotte Peugniez, Sophie Piperno-Neumann, Antoine Thyss, et al.


  • Cancers du col utérin

    by C. Balleyguier, S. Taieb, E. Zareski, S. Canale, C. Uzan, P. Duvillard, P. Pautier, C. Haie-Meder, C. Lhommé

  • Open Access

    Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking

    by Hajer Jarraya, Xavier Mirabel, Sophie Taieb, Sylvain Dewas, Emmanuelle Tresch, Francois Bonodeau, Antoine Adenis, Andrew Kramar, Eric Lartigau, Luc Ceugnart

    To describe post-CyberKnife® imaging characteristics of liver metastases as an aid in assessing response to treatment, and a novel set of combined criteria (CC) as an alternative to response according to change in size (RECIST). Imaging data and medical records of 28 patients with 40 liver metastases treated with stereotactic body radiotherapy (SBRT) were reviewed. Tumor size, CT attenuation coefficient, and contrast enhancement of lesions were evaluated up to 2 years post SBRT. Rates of local control, progression-free survival, time to progression, and overall survival according to RECIST and CC were estimated. Complete response (CR) was 3.6% (95% CI: 0.1-18%) and 18% (95% CI: 6-37%) according to RECIST and combined criteria, respectively. Two progressive diseases and two partial responses according to RECIST were classified as CR by the combined criteria and one stable response according to RECIST was classified as progressive by CC (Stuart-Maxwell test, p = 0.012). The disease control rate was 60.7% (95% CI: 41-78%) by RECIST and 64% (95% CI: 44%-81%) by CC. Use of response criteria based on change in size alone in the interpretation of liver response to SBRT may be inadequate. We propose a simple algorithm with a combination of criteria to better assess tumor response. Further studies are needed to confirm their validity.